US Biosimilar Approvals In 2021 Were Few But Included Many Firsts

 
• By David Wallace
  
Biosimilar perspectives 21-22
There are now seven FDA-approved biosimilars for adalimumab (Abbvie's Humira) • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from Biosimilars

More from Biosimilars & Generics